Effects of Pregnane X Receptor (PXR) Activation on Human Glucose, Lipid and Hormone Homeostasis

PXR-aktivaation Vaikutukset Sokeri-, Kolesteroli- ja Hormonitasapainoon

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01293422

Acronym

Rifa-2

Enrollment

Registered

2011-02-10

Start date

2011-01-31

Completion date

2011-12-31

Last updated

2012-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glucose Metabolism

Keywords

PXR, glucose, cholesterol

Brief summary

This clinical trial is designed to study the effects of pregnane X receptor activator rifampicin on the glucose, lipid and hormone homeostasis in healthy volunteers. The main hypothesis is that rifampicin raises postprandial glucose studied with oral glucose tolerance test. The study is a non-randomized, one-phase, open-label trial. Twelve subjects will be given 600 mg of rifampicin a day for a week. The main outcome measures are the changes in the glucose and insulin levels during oral glucose tolerance test.

Interventions

DRUGRifampicin

Rifampicin 600 mg daily for a week

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy volunteer * Age 18-45 years * Body mass index 19-28

Exclusion criteria

* Any continuous medication * Any significant disease * Allergy to rifampicin * Pregnancy and breast feeding * Fear of needles and previous difficult blood samplings * Substance abuse * Participation in another clinical drug trial within 1 month of enrollment * Use of soft contact lenses

Design outcomes

Primary

Measure	Time frame
Glucose levels during oral glucose tolerance test	—

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026